Jim Cramer on Eli Lilly's Covid-19 phase 2 trial results for antibody drug

Eli Lilly announced on Wednesday it had found proof of concept data from an interim analysis of the BLAZE-1 clinical trial that showed a reduced rate of hospitalization for coronavirus patients treated with its neutralizing antibody drug. CNBC's "Squawk on the Street" crew discusses the status of getting a coronavirus candidate approved and what it could mean for the markets and the economy.
Wed, Sep 16 202010:29 AM EDT